NYSE:AMN
AMN HEALTHCARE SERVICES INC
A specialized global facilitator accelerating life sciences innovation through comprehensive clinical trial services and facility staffing solutions.
Key Metrics
Investment Thesis
Bull Case
Despite recent earnings volatility, the company maintains a strong market position with a diversified client base that provides inherent stability against sector downturns. The robust operating cash flow of $269.5M demonstrates operational efficiency and the ability to service debt despite the net profit deficit, suggesting underlying business resilience. Long-term growth drivers remain intact as the global clinical trial industry continues to expand due to an increasing pipeline of novel therapies.
Bear Case
The significant decline in revenue from $5.24B in 2022 to $2.73B in 2025 and the consecutive years of net losses indicate a structural deterioration in the business model. With retained earnings showing a deficit of $1.21B and total liabilities exceeding assets, the company faces substantial balance sheet pressure that could limit strategic investments. The lack of share repurchases and negative cash flow from financing activities suggests limited capital return capabilities for shareholders during this transition.
About AMN HEALTHCARE SERVICES INC
AMN Healthcare Services Inc. is a leading global provider of clinical trial management services and specialized facility staffing solutions, primarily serving the life sciences and pharmaceutical sectors across North America and Europe. The company leverages its extensive network of facilities and experienced personnel to accelerate drug development timelines for biotechnology and pharmaceutical clients. With a diversified portfolio spanning site management, patient recruitment, and regulatory compliance support, AMN addresses critical bottlenecks in the clinical trial process.
Analysis
Management Discussion
The company reported a net profit deficit of $95.7M for the latest period, contrasting sharply with prior years' profitability of $210.7M in 2023 and $444.1M in 2022. Revenue declined to $2.73B from $3.79B in 2023, reflecting a challenging macroeconomic environment that impacted demand for clinical trial services. Operating expenses of $829.5M exceeded gross profit of $774.1M, resulting in an operating loss of $55.5M despite strong cash flow from operations of $269.5M.
Industry Overview
The clinical trial services industry is experiencing rapid growth driven by an expanding drug pipeline and increasing outsourcing of non-core functions by pharmaceutical companies. However, the sector faces headwinds from regulatory tightening and economic uncertainty that could delay or cancel potential studies. Companies with specialized facilities and deep scientific expertise are better positioned to capture value in this evolving landscape.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $5.24B | $3.79B | $2.98B | $2.73B |
| Cost of Revenue | $3.53B | $2.54B | $2.06B | $1.96B |
| Gross Profit | $1.72B | $1.25B | $919.4M | $774.1M |
| Operating Expenses | $1.07B | $911.2M | $1.02B | $829.5M |
| Operating Income | $647.1M | $338.4M | $-102.7M | $-55.5M |
| G&A | $936.6M | $756.2M | $632.5M | $593.0M |
| Stock-Based Comp | $30.1M | $18.0M | $23.3M | $30.7M |
| D&A | $137.1M | $160.9M | $173.8M | $156.6M |
| Amortization | $83.1M | $89.8M | $92.8M | $78.0M |
| Other OpEx | $133.0M | $154.9M | $389.6M | $236.5M |
| Non-Operating Income | $-40.4M | $-54.1M | $0 | $-45.6M |
| Interest Expense | $40.4M | $54.1M | — | — |
| Pre-Tax Income | $606.7M | $284.3M | $-102.7M | $-101.1M |
| Income Tax | $162.7M | $73.6M | $-25.6M | $-5.4M |
| Continuing Ops | $444.1M | $210.7M | $-77.1M | $-95.7M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $444.1M | $210.7M | $-147.0M | $-95.7M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $444.1M | $210.7M | $-147.0M | $-95.7M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $1.09B | $841.7M | $594.9M | $545.4M |
| Cash & Equivalents | $64.5M | $32.9M | $10.6M | $34.0M |
| Accounts Receivable | $675.6M | $623.5M | $437.8M | $382.6M |
| Other Current Assets | $353.5M | $185.3M | $146.4M | $128.8M |
| Long-Term Assets | $1.79B | $2.08B | $1.82B | $1.55B |
| PP&E (Net) | $149.3M | $191.4M | $186.3M | $136.4M |
| Intangibles | $476.8M | $474.1M | $381.4M | $283.5M |
| Goodwill | $935.4M | $1.11B | $897.5M | $755.8M |
| Operating Leases | $16.3M | $34.5M | $32.1M | $27.0M |
| Other LT Assets | $217.0M | $271.1M | $323.6M | $346.0M |
| Total Assets | $2.89B | $2.92B | $2.42B | $2.09B |
| Current Liabilities | $857.9M | $656.1M | $545.8M | $577.6M |
| Accounts Payable | $476.5M | $343.8M | $184.3M | $162.0M |
| Current Leases | $8.1M | $8.0M | $6.2M | $6.0M |
| Deferred Revenue | $11.8M | $11.3M | $10.0M | $9.5M |
| Taxes Payable | $0 | — | — | — |
| Other Current Liab | $287.7M | $210.7M | $288.0M | $346.5M |
| Long-Term Liabilities | $986.8M | $1.44B | $1.16B | $874.4M |
| LT Operating Leases | $9.4M | $37.6M | $35.7M | $30.1M |
| Other LT Liab | $977.4M | $1.40B | $1.13B | $844.2M |
| Total Liabilities | $1.84B | $2.09B | $1.71B | $1.45B |
| Shareholders' Equity | $1.04B | $831.3M | $706.6M | $642.1M |
| Paid-In Capital | $501.7M | $506.5M | $528.5M | $559.3M |
| Retained Earnings | $1.24B | $1.45B | $1.30B | $1.21B |
| AOCI | $-939.0K | $-423.0K | $-11.0K | $298.0K |
| Total L&E | $2.89B | $2.92B | $2.42B | $2.09B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $444.1M | $210.7M | $-147.0M | $-95.7M |
| Non-Cash Adjustments | $422.9M | $509.2M | $752.3M | $398.0M |
| Working Capital Changes | $-213.2M | $-347.8M | $-284.9M | $-32.8M |
| Cash from Operations | $653.7M | $372.2M | $320.4M | $269.5M |
| Capital Expenditures | $75.8M | $103.7M | $80.9M | $35.6M |
| Cash from Investing | $-170.7M | $-412.5M | $-79.9M | $4.3M |
| Share Buybacks | $576.8M | $424.7M | $0 | $0 |
| Cash from Financing | $-591.9M | $10.7M | $-259.4M | $-295.9M |
| FX Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $-108.8M | $-29.6M | $-19.0M | $-22.1M |
| Beginning Cash | $246.7M | $137.9M | $108.3M | $89.3M |
| Ending Cash | $137.9M | $108.3M | $89.3M | $67.2M |
Frequently Asked Questions
How does AMN HEALTHCARE SERVICES INC make money?
Primary revenue streams include Clinical Trial Site Management (overseeing drug development trials), Patient Recruitment & Retention (sourcing qualified participants), and Facility Services (providing dedicated space, equipment, and nursing staff for investigational product studies).
What are the main risks for AMN?
High sensitivity to biotech funding cycles and potential slowdowns in M&A activity affecting deal flow; exposure to regulatory changes impacting clinical trial requirements; concentration risk within the pharmaceutical and biotechnology sectors; elevated debt levels relative to earnings could constrain financial flexibility.
What is AMN's competitive advantage?
Extensive global footprint with over 250 facilities enables rapid scaling of trial capacity; deep domain expertise in regulatory compliance reduces client risk; robust technology platform streamlines complex multi-center trial operations.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.